Key result
The DVVconfirm assay was highly sensitive to the anticoagulant effect of rivaroxaban and demonstrated a strong correlation with prothrombin time in patients on vitamin K antagonists (r=0.78).
Why the study?
Does the DVVconfirm assay accurately measure the anticoagulant effect of rivaroxaban in treated patients?
Observational (n=220)
Does the DVVconfirm assay accurately measure the anticoagulant effect of rivaroxaban in treated patients?
Effect estimate: r = 0.78 (95% CI 0.71-0.84)
p-value: p=<0.001
The DVVconfirm assay using Russell's viper venom provides a rapid and sensitive method for measuring the anticoagulant effect of rivaroxaban in whole plasma.
No takes yet. Share an insight, caveat, or question.
Supports DVVconfirm for rivaroxaban effect assessment; leaves open prospective validation before clinical adoption.
Altman et al. (2014) conducted an observational in Patients requiring anticoagulation (Atrial Fibrillation, Deep Vein Thrombosis) (n=220). DVVconfirm assay vs. Standard coagulation assays (PT, aPTT, TT) was evaluated on Correlation between R-PT and R-C (DVVconfirm ratio) in patients treated with warfarin (r = 0.78, 95% CI 0.71-0.84, p=<0.001). The DVVconfirm assay was highly sensitive to the anticoagulant effect of rivaroxaban and demonstrated a strong correlation with prothrombin time in patients on vitamin K antagonists (r=0.78).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: